Illumina Shares Fall After Disclosing SEC Investigation Into Grail Deal
By Will Feuer
Shares of Illumina slid more than 4% after the gene-sequencing company disclosed that the Securities and Exchange Commission is investigating the company's $7 billion takeover of cancer-test developer Grail.
The company said in a securities filing late Thursday that SEC staff in July requested documents and communications related to Illumina's buyout of Grail. The regulators also requested certain statements and disclosures concerning Grail, its products and the acquisition, as well as the conduct and compensation of certain members of Illumina and Grail management, among other things.
Illumina said it is cooperating with the investigation.
The stock fell 4.3% to $177.19 in midday trading. So far this year, shares have fallen more than 12%.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
August 11, 2023 13:17 ET (17:17 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact